



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

**Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts**

**Public declaration of interests**

**I, JOAQUIN MATEO**

**Organisation/Company:** VALL D'HEBRON INSTITUTE OF ONCOLOGY

**Country:** Spain

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2018-(current)	AstraZeneca	olaparib	prostate cancer
01/2018-12/2019	Janssen	participation in advisory boards about prostate cancer	
01/2019-09/2019	Amgen	participation in advisory boards about prostate cancer	
09/2019-09/2019	Clovis Oncology	Rucaparib	prostate cancer
02/2020-02/2020	MSD	participation in advisory boards about prostate cancer	

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

No interest declared

2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2018-(current)	AstraZeneca	Olaparib	prostate cancer
01/2019-(current)	Beigene	Pamiparib	Prostate Cancer
01/2020-(current)	Pfizer	talazoparib	prostate cancer

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
01/2018-(current)	AstraZeneca	many different clinical trials	prostate cancer
01/2018-(current)	Bayer	many different clinical trials	prostate cancer
01/2018-(current)	Astellas	many different clinical trials	prostate cancer
01/2018-(current)	Janssen	many different clinical trials	prostate cancer
01/2018-(current)	Merck	many different clinical trials	prostate cancer
01/2018-(current)	MSD	many different clinical trials	prostate cancer
01/2018-(current)	Roche	many different clinical trials	prostate cancer
01/2018-(current)	Amgen	many different clinical trials	prostate cancer

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
AstraZeneca	development of olaparib in prostate cancer
Pfizer	development of talazoparib in prostate cancer

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

I am involved in academic clinical trials involving drugs from Pfizer

I chair the Precision Medicine Working Group of the European Society of Medical Oncology (ESMO); no financial interest but we have regular meetings to discuss projects with pharma industry representatives.

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

**"EMA Activities"** encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

**"Confidential Information"** means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

**"Confidential Documents"** mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

<b>Full Name:</b>	JOAQUIN MATEO VALDERRAMA
<b>Date:</b>	2020-04-16

*For Definitions of activities etc, refer to Policy on Handling of Conflicts of Interest / Electronic DOI template*